CTLA4 and neoplasm: In murine models of osteosarcoma and colorectal cancer, co-administration of anti-CTLA-4 mAb with either tumor lysate-loaded or immature DCs resulted in tumor growth inhibition, reduced metastasis, and enhanced survival (83, 84).